Ho, P. J., Quach, H., Delimpasi, S., Santoro, A., Lee, C. H., Kint, N., Faict, S., Yu, Y., Catalani, O., Mishra, A., Tyagi, T., Devlin, C., Sheikh, S., Dimopoulos, M. (2025). Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study. Blood. https://doi.org/10.1182/blood-2025-700